GRADE研究中基线因素与血糖结局的关联:一项比较有效性随机临床试验
GRADE研究纳入病程<10年、使用二甲双胍且HbA1c 6.8-8.5%的2型糖尿病患者5047例,随机分配至甘精胰岛素、格列美脲、利拉鲁肽或西格列汀。分析显示年轻年龄、西班牙裔、较高基线HbA1c、空腹血糖和甘油三酯、较低胰岛素分泌及较高胰岛素抵抗与血糖结局相关,但无因素与四种药物疗效差异相关。第4年未能维持HbA1c<7%主要由年轻年龄和较高基线HbA1c驱动。
要点
- 年轻年龄、较高基线HbA1c和空腹血糖共同与第4年血糖结局相关。
- 甘精胰岛素和利拉鲁肽在第4年的优效性在控制多个基线因素后仍持续。
- 无基线因素与四种药物疗效差异相关。
核心结论
- 多个基线因素与血糖结局相关,但与四种药物的疗效差异无关。
- 未能维持HbA1c<7%主要由年轻年龄和较高基线HbA1c驱动。
- 预测早期血糖恶化的因素有助于针对患者进行更积极的管理。
研究设计与样本
- GRADE研究为比较有效性随机临床试验,纳入病程<10年、使用二甲双胍、HbA1c 6.8-8.5%的2型糖尿病患者5047例。
- 参与者随机分配至甘精胰岛素、格列美脲、利拉鲁肽或西格列汀。
- 血糖结局定义为HbA1c≥7.0%并随后确认。
- 采用单变量和多变量回归及分类回归树(CART)分析评估基线因素与第1年和第4年血糖结局的关联。
主要发现
- 单变量分析中,年轻年龄(<58岁)、西班牙裔、较高HbA1c、空腹血糖和甘油三酯水平、较低胰岛素分泌及相对较高胰岛素抵抗与第1年和/或第4年血糖结局相关。
- 第4年时无因素与药物疗效差异相关。
- 多变量分析中,治疗组、年轻年龄及较高基线HbA1c和空腹血糖共同与第4年血糖结局相关。
- 控制多个基线因素后,甘精胰岛素和利拉鲁肽在第4年的优效性仍持续。
- CART分析表明,年轻参与者及基线HbA1c≥7.4%者第4年未能维持HbA1c<7%的可能性更大。
临床怎么用
- 作者认为,预测早期血糖恶化的因素有助于针对患者进行更积极的管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the individual and joint associations of baseline factors with glycemia, and also with differential effectiveness of medications added to metformin. RESEARCH DESIGN AND METHODS: Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) participants (with type 2 diabetes diagnosed for <10 years, on metformin, and with HbA1c 6.8-8.5%; N = 5,047) were randomly assigned to a basal insulin (glargine), sulfonylurea (glimepiride), glucagon-like peptide 1 agonist (liraglutide), or dipeptidyl peptidase 4 inhibitor (sitagliptin). The glycemic outcome was HbA1c ≥7.0%, subsequently confirmed. Univariate and multivariate regression and classification and regression tree (CART) analyses were used to assess the association of baseline factors with the glycemic outcome at years 1 and 4. RESULTS: In univariate analyses at baseline, younger age (<58 years), Hispanic ethnicity, higher HbA1c, fasting glucose, and triglyceride levels, lower insulin secretion, and relatively greater insulin resistance were associated with the glycemic outcome at years 1 and/or 4. No factors were associated with differential effectiveness of the medications by year 4. In multivariate analyses, treatment group, younger age, and higher baseline HbA1c and fasting glucose were jointly associated with the glycemic outcome by year 4. The superiority of glargine and liraglutide at year 4 persisted after multiple baseline factors were controlled for. CART analyses indicated that failure to maintain HbA1c <7% by year 4 was more likely for younger participants and those with baseline HbA1c ≥7.4%. CONCLUSIONS: Several baseline factors were associated with the glycemic outcome but not with differential effectiveness of the four medications. Failure to maintain HbA1c <7% was largely driven by younger age and higher HbA1c at baseline. Factors that predict earlier glycemic deterioration could help in targeting patients for more aggressive management.
引用
- Garvey WT, Cohen RM, Butera NM, et al. Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial. Diabetes Care. 2024. PMID: 38285957. doi:10.2337/dc23-1782
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。